Gene Therapy: Navigating Progress, Challenges, and a Changing Regulatory Landscape

The field of gene therapy is at a pivotal moment, marked by both remarkable successes and significant hurdles. While over 50 gene therapies have gained global approval, and innovative treatments like personalized gene editing are emerging, 2025 presented challenges including safety concerns, manufacturing costs, and regulatory setbacks. A new wave of regulatory changes is underway, aiming to accelerate access to these potentially curative treatments, but questions remain about balancing speed with patient safety.

Recent Successes and Emerging Technologies

Gene therapy has demonstrated its potential with the rapid development of a personalized gene-editing therapy for a newborn with a severe metabolic disorder, and the first clinical reports of prime editing in patients with immunodeficiency. These advancements highlight the speed at which new technologies can move from the lab to the clinic. The field continues to innovate, with ongoing development of new vectors, methods to minimize off-target effects, and improved delivery approaches.

A Challenging Year for Gene Therapy Development

Despite these successes, the total number of gene therapies in active development declined in 2025, reversing a previous upward trend. This shift is attributed to a pullback from preclinical research and restructuring within biotech and pharmaceutical companies, leading to program terminations and layoffs. Concerns about safety resurfaced following patient deaths linked to gene therapies for Duchenne muscular dystrophy and amyloidosis, prompting temporary holds on several trials. High manufacturing costs and limited adoption similarly led to the discontinuation of a gene therapy for hemophilia B shortly after its approval.

Evolving Regulatory Pathways

The regulatory landscape is undergoing significant changes. The U.S. Food and Drug Administration (FDA) announced new guidance for cell and gene therapies in late 2025, and unveiled a “plausible mechanism pathway” in November 2025 designed to accelerate the approval of personalized gene-editing therapies. This new program aims to build on the success of treatments like that for “baby KJ” and potentially offer access to treatments for the estimated 300 million patients with rare genetic disorders. The FDA will prioritize rare and fatal diseases, particularly those with no alternative treatments.

In February 2026, the FDA proposed a framework to speed approvals of personalized treatments for rare and life-threatening genetic diseases, allowing drugmakers to rely on more limited data. This contrasts with the more cautious approach of the European Medicines Agency, which utilizes conditional approval pathways. China is actively developing new technologies but has seen slower market adoption, with only one gene therapy approved beyond CAR T-cell products, though new National Medical Products Administration guidelines, effective in spring 2026, aim to streamline the review process and encourage investment.

The Importance of Collaboration and Data Sharing

Maintaining momentum in gene therapy requires sustained investment and predictable regulatory pathways. The field relies heavily on academic research for the development of new technologies. Increased collaboration between academia and industry is crucial. Transparent data sharing, including results from terminated trials, is essential for patient safety and informing future development. Currently, much of this data remains unpublished beyond regulatory reports and press releases, representing a lost opportunity for learning and improvement.

Looking Ahead

Gene therapies hold the potential for one-time curative treatments for many severe diseases. To fully realize this promise, continued investment, robust regulatory frameworks, and a commitment to transparency and collaboration are paramount. Addressing the current challenges and navigating the evolving regulatory landscape will be critical to ensuring that these life-changing therapies reach the patients who demand them.